Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell MAGE-A1 MAGE-A3 NY-ESO-1 peptide vaccine
- Development stage
- Unknown
- Lead developer
- University of Louisville
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
An investigational, patient-specific **autologous dendritic cell cancer vaccine** developed by the University of Louisville for relapsed pediatric neuroblastoma and sarcomas. The product is generated from each patient's dendritic cells and pulsed ex vivo with overlapping peptide pools derived from the cancer-testis antigens MAGE-A1, MAGE-A3, and NY-ESO-1. After administration, the antigen-loaded dendritic cells are intended to prime or expand tumor-antigen-specific T-cell responses against tumor cells expressing these antigens. It was evaluated after decitabine pretreatment, which was administered separately to increase cancer-testis antigen expression; decitabine is not a component of the vaccine product. ([link.springer.com](https://link.springer.com/content/pdf/10.1007/s00262-015-1731-3.pdf))
- Other names
- autologous cancer-testis antigen-specific dendritic cell vaccineautologous dendritic cell vaccine with adjuvantautologous dendritic cell MAGE-A1 MAGE-A3 NY-ESO-1 vaccine
Beyond the preview
Go deeper on autologous dendritic cell MAGE-A1 MAGE-A3 NY-ESO-1 peptide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell MAGE-A1 MAGE-A3 NY-ESO-1 peptide vaccine.